Biogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA™ (Daclizumab) for Treatment of Multiple Sclerosis
Go back to Biogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA™ (Daclizumab) for Treatment of Multiple Sclerosis| AbbVie (NYSE: ABBV) | Delayed: 263.96 -0.06 (0.02%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $264.02 | 52 Week High | $68.12 | |||
| Open | $263.29 | 52 Week Low | $50.71 | |||
| Day High | $266.34 | P/E | 57.26 | |||
| Day Low | $262.44 | EPS | $4.61 | |||
| Volume | 8,162,686 | |||||
| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 215.50 -3.55 (1.62%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $219.05 | 52 Week High | $333.65 | |||
| Open | $219.05 | 52 Week Low | $223.02 | |||
| Day High | $220.17 | P/E | 27.59 | |||
| Day Low | $215.26 | EPS | $7.81 | |||
| Volume | 2,634,719 | |||||
